| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 640.4 | 689.1 | 601.8 |
| Other income | 22.4 | 22.8 | 9.0 |
| Total income | 662.8 | 711.9 | 610.8 |
| Profit before exceptional items & tax | 212.2 | 215.8 | 163.0 |
| Profit before tax | 212.2 | 215.8 | 163.0 |
| Net profit | 160.1 | 162.7 | 121.5 |
| Operating margin | 32.0% | 30.3% | 26.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +31.80% |
|---|---|
| Net profit, quarter on quarter | -1.60% |
| Revenue, year on year | +6.40% |
| Operating profit, year on year | +22.40% |
| Operating profit, quarter on quarter | -1.60% |
NSE results filing, NSE: ALIVUS. Figures extracted from the filing.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,365.60
- Market cap
- ₹16,766 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 27.8×Sector 50.4×
- Promoter holding
- 74.87%+0.00% QoQ
- FII holding
- 5.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Merger & Restructuring Worth ₹0.9 Cr
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
- Value
- ₹0.90 Cr
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus Life Sciences Earnings Call Transcript: Key Takeaways
Alivus reported strong Q1 FY27 results with 6.4% revenue growth, masking a massive 52.6% decline in its legacy GPL business through high-margin non-GPL growth and operational efficiencies.
- Call
- Guides 11% growth
Alivus Life Sciences Investor Presentation: Key Takeaways
Alivus Life Sciences delivered strong Q1FY27 performance with revenue at ₹6,404 Mn and EBITDA margins expanding to 36.6%. The company is pivoting towards Non-GPL segments and CDMO growth.
- Call
- Guides 11% growth
Alivus Life Sciences Earnings Call: Key Takeaways
Alivus (ex-Glenmark Life Sciences) reported strong Q4FY26 results with record 33.6% EBITDA margins, driven by non-GPL growth (71% of business) and CDMO recovery.
Alivus Life Sciences Earnings Call: Key Takeaways
Alivus (formerly Glenmark Life Sciences) delivered record FY26 EBITDA margins of 33.6%, shifting successfully from GPL dependency to a more profitable non-GPL segment despite a major plant fire and global headwinds.